The US Food and Drug Administration (FDA) has placed bluebird bio’s (Nasdaq: BLUE) Phase I/II and Phase III studies of LentiGlobin gene therapy for sickle cell disease (SCD) on a clinical hold.
This action from the FDA comes after the US biotech voluntarily suspended the studies temporarily following a reported suspected unexpected serious adverse reaction (SUSAR) of acute myeloid leukemia (AML), news that sent bluebird's share price to drop 38% lower in a single day last week.
In line with the clinical study protocols for the trial, bluebird bio had placed the studies on temporary suspension following a report received earlier this month that a patient who was treated more than five years ago in the Phase I/II study was diagnosed with AML.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze